Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded at Wells Fargo & Company

Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from an equal weight rating to an overweight rating in a report released on Thursday morning, MarketBeat Ratings reports. Wells Fargo & Company currently has $170.00 target price on the specialty pharmaceutical company’s stock, up from their previous target price of $130.00.

Other equities research analysts also recently issued reports about the stock. TD Cowen decreased their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Robert W. Baird raised their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Royal Bank of Canada reiterated an “outperform” rating and set a $179.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Finally, Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Buy” and an average target price of $180.33.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $133.96 on Thursday. The company has a market cap of $8.10 billion, a P/E ratio of 18.87, a PEG ratio of 0.92 and a beta of 0.56. The company has a fifty day simple moving average of $123.47 and a 200 day simple moving average of $117.22. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $138.27.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the transaction, the chief executive officer now owns 425,525 shares in the company, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 5,053 shares of company stock worth $617,442 in the last quarter. Insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. AQR Arbitrage LLC bought a new position in Jazz Pharmaceuticals during the fourth quarter worth about $5,150,000. Darwin Global Management Ltd. bought a new position in Jazz Pharmaceuticals in the 4th quarter worth approximately $59,668,000. AdvisorShares Investments LLC boosted its holdings in Jazz Pharmaceuticals by 113.5% in the 4th quarter. AdvisorShares Investments LLC now owns 10,460 shares of the specialty pharmaceutical company’s stock worth $1,288,000 after buying an additional 5,560 shares during the period. Northern Trust Corp grew its stake in Jazz Pharmaceuticals by 18.9% in the 4th quarter. Northern Trust Corp now owns 521,196 shares of the specialty pharmaceutical company’s stock valued at $64,185,000 after buying an additional 82,817 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Jazz Pharmaceuticals by 1.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 353,467 shares of the specialty pharmaceutical company’s stock valued at $43,529,000 after acquiring an additional 5,715 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.